Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
Eugia Pharma Specialities restarts production at terminally sterilized product lines
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
BHL will undertake the development and supply of these molecules
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
Subscribe To Our Newsletter & Stay Updated
